The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial
Authors' conclusion
In this study, empagliflozin did not demonstrate anti-inflammatory effects but yielded possibly meaningful uricosuric effects in non-diabetic patients with overweight or obesity. Moreover, adipose tissue dysfunction remained unaltered.
Study context
- Population
- Outpatients with body mass index (BMI) > 28 kg/m² and risk factors for heart failure (HF), excluding diabetes; median age 68 years, median BMI 31.6 kg/m²randomised
- Participants
- 92 outpatients
- Comparison
- Empagliflozin 10 mg vs placebo for 180 days
- Empagliflozinn = 44
- Placebon = 48reference
- Primary endpoint
- Pre-defined endpoints: baseline-adjusted estimated treatment differences (ETD) or ratios (ETR) for IL-6, high-sensitive C-reactive protein (hsCRP) and uric acid
- Follow-up
- 180 days
Methodological detailspre-defined secondary analysis, placebo-controlled
- Pre-defined secondary analysis
- Placebo-controlled
Primary result
As reported in the abstract
IL-6, hsCRP and uric acid
Estimate (95% CI)P value
Empagliflozinvs Placebo
ETR (IL-6) 1.03(0.82–1.30)
P = 0.78Empagliflozinvs Placebo
ETR (hsCRP) 1.15(0.87–1.51)
P = 0.33- Between Empagliflozin and Placebo · uric acid decreased
- Estimated treatment differences (ETD) (uric acid) - 0.06 mmol/l (95% CI - 0.08 to - 0.04); P < 0.0001
Further findings
Adipose tissue gene expression (markers of dysfunction, incl. inflammation)
- No changes in adipose tissue gene expression were observed
- Exploratory
Original publication
The effect of empagliflozin on inflammation in patients with overweight or obesity and risk of heart failure: a substudy from the Empire Prevent Metabolic trial. Cardiovasc Diabetol. Published 12 June 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →